MESO MESOBLAST LTD IFRS
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1345099 · Fiscal year ends 06/30
Financial factors as of 2025-06-30 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY191.4%
TTM net income YoY-16.1%
TTM EPS YoY5.1%
Revenue 3-yr CAGR19.0%
Net income 3-yr CAGR—
Margins
Gross margin70.2%
Operating margin—
Net margin-593.9%
FCF margin-294.4%
EBITDA margin—
Returns
ROE-19.0%
ROA-14.1%
ROIC (approx.)—
Asset turnover0.02x
Leverage & solvency
Liabilities / assets23.9%
Debt / equity0.20x
Current ratio1.99x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.49x
Accruals ratio-7.2%
Payout ratio—
Capex / revenue4.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-06-30 | FY20242024-06-30 |
|---|---|---|
| Income statement | ||
| Revenue | $17.20M | $5.90M |
| Cost of revenue | $5.13M | $0 |
| Gross profit | $12.07M | $5.90M |
| R&D expense | $34.81M | $39.72M |
| SG&A expense | $39.31M | $24.98M |
| Interest expense | $21.75M | $20.66M |
| Pretax income | -$101.81M | -$88.15M |
| Income tax | $330,000 | -$191,000 |
| Net income | -$102.14M | -$87.96M |
| EPS (basic) | -0.08 | -0.09 |
| EPS (diluted) | -0.08 | -0.09 |
| Weighted avg. shares (diluted) | 1.21B | 986.70M |
| Balance sheet | ||
| Cash & equivalents | $161.55M | $62.96M |
| Receivables | $14.87M | $20.95M |
| Inventory | $22.25M | $0 |
| Current assets | $204.35M | $86.46M |
| PP&E, netmay include right-of-use assets (IFRS) | $1.70M | $1.11M |
| Total assets | $784.68M | $669.15M |
| Current liabilities | $102.63M | $73.24M |
| Short-term debt | $54.16M | $13.86M |
| Long-term debt | $67.74M | $100.48M |
| Total debt | $121.89M | $114.34M |
| Total liabilities | $187.24M | $188.80M |
| Shareholders' equity | $597.44M | $480.36M |
| Net debt | -$39.66M | $51.38M |
| Cash flow statement | ||
| Operating cash flow | -$49.95M | -$48.46M |
| Capital expenditure | $680,000 | $271,000 |
| Free cash flow | -$50.63M | -$48.73M |
| Investing cash flow | $120,000 | -$97,000 |
| Financing cash flow | $147.34M | $40.25M |
| Depreciation & amortization | $2.46M | $4.67M |
| Stock-based compensation | $22.09M | $5.87M |
Free plan shows the latest 2 periods; Pro shows all 10 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.